Some investors and analysts believe the pharma’s $6.7 billion offer is justified given Terns’ recent stock run. Others are ...
If consummated, the deal would hand Merck a treatment that could challenge Novartis’ fast-selling Scemblix. But the low ...
Terns Pharmaceuticals' stock has moved up recently due to promising Phase 1 data from its obesity candidate TERN-601. TERN-701, targeting CML, is in Phase 1 with interim data expected in December 2024 ...
Chuck described in his recent Night Dive entry our evening dive operations. To date, we have set the buoy (marking our intended night site) out in the afternoon several more times than we have been ...
FOSTER CITY, Calif. - Terns Pharmaceuticals, Inc. (NASDAQ:TERN), a $712 million market cap biotech company whose stock has surged over 210% in the past six months, announced Tuesday it will ...
Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study, positioning TERN competitively in the obesity drug market. The commercial viability of TERN-601's manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results